NCT02970643View on ClinicalTrials.gov

Proof-of-Concept Trial of Palonosetron and Olanzapine Without Dexamethasone for the Prevention of CIN

NAUnknownINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

September 30, 2017

Study Completion Date

December 31, 2017

Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
DRUG

Olanzapine

Moderate risk chemotherapy induced nausea group in all cancer. D1 Olanzapine 10mg PO D2-3 Olanzapine 10mg PO

DRUG

Palonosetron

Moderate risk chemotherapy induced nausea group in all cancer. D1 Palonosetron 0.25mg IV

Sponsors

Collaborators (1)

HK inno.N Corporation
All Listed Sponsors
collaborator

HK inno.N Corporation

INDUSTRY

lead

Hee Jun Kim

OTHER

NCT02970643 - Proof-of-Concept Trial of Palonosetron and Olanzapine Without Dexamethasone for the Prevention of CIN | Biotech Hunter | Biotech Hunter